Abstract | OBJECTIVE: RESULTS: CONCLUSIONS: The present study identifies the ARB/ PPARgamma modulator telmisartan as a partial PPARalpha agonist. As a result of its particular pharmacokinetic profile, PPARalpha activation by telmisartan seems to be restricted to the liver. Hepatic PPARalpha activation may provide an explanation for telmisartan's antidyslipidemic actions observed in recent clinical trials.
|
Authors | Markus Clemenz, Nikolaj Frost, Michael Schupp, Sandrine Caron, Anna Foryst-Ludwig, Christian Böhm, Martin Hartge, Ronald Gust, Bart Staels, Thomas Unger, Ulrich Kintscher |
Journal | Diabetes
(Diabetes)
Vol. 57
Issue 5
Pg. 1405-13
(May 2008)
ISSN: 1939-327X [Electronic] United States |
PMID | 18184928
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Benzimidazoles
- Benzoates
- PPAR alpha
- RNA, Small Interfering
- Telmisartan
|
Topics |
- Angiotensin II Type 1 Receptor Blockers
(pharmacology)
- Animals
- Benzimidazoles
(pharmacology)
- Benzoates
(pharmacology)
- Cell Line
- Cell Line, Tumor
- Gene Expression Regulation
(drug effects)
- Gene Silencing
- Genes, Reporter
- Humans
- Liver
(drug effects, physiology)
- Liver Neoplasms
- Male
- Mice
- Mice, Inbred C57BL
- PPAR alpha
(genetics)
- Polymerase Chain Reaction
- RNA, Small Interfering
(genetics)
- Telmisartan
- Transcriptional Activation
- Transfection
|